17,261 trials
Arthritis, Rheumatoid
Primary: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 2; 3; 1 Participants
Primary Immunodeficiency · PID
Primary: Safety: Death — 4 Participants
HER2-positive Breast Cancer · Metastatic Breast Cancer
Primary: Progression Free Survival — 4.6 months
Bladder Cancer · Melanoma
Primary: Confirmed Objective Response in Bladder Cancer Participants to Nivolumab Monotherapy — 23 percentage of participants with PR/CR
Hypertension · Aging · Sedentary Lifestyle
Primary: Change in Gait Speed From Baseline — 0.10; 0.05; 0.10 m/sec
Desmoplastic Small Round Cell Tumor
Primary: Progression Free Survival (PFS) — NA; NA Months
Sickle Cell Disease (SCD)
Primary: Pharmacokinetics (PK): AUCd15 of Crizanlizumab After First Dose - Part A — 10500; 8180; 20600; 14400 hr*ug/mL
Atopic Eczema/Dermatitis (Non-Specific)
Primary: Change in Epidermal Thickness — -31.66; -13.76; -28.65; -14.41 µm
Obesity · Obese · Overweight or Obesity
Primary: Change From Baseline in Body Weight at Week 48 — -3.31; -5.99; -9.25; -9.76 kilogram (kg) — p=<0.001
Chronic Pain
Primary: The Pittsburgh Sleep Quality Index (PSQI): PSQI Total Score at Baseline — 11.20; 9.78 Score on scale
Primary Sjögren's Syndrome
Primary: Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24 — 45.5; 11.1 Percentage of participants
Pancreatic Cancer
Primary: Maximum Tolerated Dose (Phase 1) — 45 Gy
Melanoma
Primary: Pathologic Response Rate (pRR) for Cohort 1 as Determined by Independent Pathologic Review — 77.3; 80.0; 45.0; 60.0 percentage of participants
Tobacco Use Disorder · Nicotine Addiction
Primary: Change in Nicotine Self-Administration — -0.8; -0.5 Number of cigarettes
Transthyretin Amyloidosis
Primary: Median of Uptake of Evuzamitide as Measured by Volume of Interest in Milliliters — 78.7; 253.6; 177.2; 39.6 mL